Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials-Reference-Cited by-同舟云学术

Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials

Published:2010-06-10 Issue:8 Volume:24 Page:1422-1428
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Sander A,Zimmermann M,Dworzak M,Fleischhack G,von Neuhoff C,Reinhardt D,Kaspers G J L,Creutzig U

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2010127.pdf

Reference27 articles.

1. Kaspers GJL, Creutzig U . Pediatric acute myeloid leukemia: international progress and future directions. Leukemia 2005; 19: 2025–2029.

2. Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005; 19: 2030–2042.

3. Aladjidi N, Auvrignon A, Leblanc T, Perel Y, Benard A, Bordigoni P et al. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. J Clin Oncol 2003; 21: 4377–4385.

4. Rubnitz JE, Razzouk BI, Lensing S, Pounds S, Pui CH, Ribeiro RC . Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. Cancer 2007; 109: 157–163.

5. Stahnke K, Boos J, Bender-Gotze C, Ritter J, Zimmermann M, Creutzig U . Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia. Leukemia 1998; 12: 1534–1538.

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients;British Journal of Haematology;2024-07-31

2. Navigating Treatment Options and Communication in Relapsed Pediatric AML;American Society of Clinical Oncology Educational Book;2024-06

3. Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium;Cancers;2024-01-24

4. Refractory/Relapsed AML in Children and Evolution of Novel Therapies;Pediatric Oncology;2024

5. Gemtuzumab ozogamicin for relapsed or primary refractory acute myeloid leukemia in children—the Polish Pediatric Leukemia and Lymphoma Study Group experience;Frontiers in Immunology;2023-12-22